GLP-1 Against Brain Protein Aggregation: Targeting Amyloid, Tau, and Alpha-Synuclein

Review of GLP-1 effects on amyloid-beta, tau, and alpha-synuclein covers how GLP-1 drugs may protect against the three major neurodegenerative protein aggregates.

Au, Hezekiah C T et al.·Neuroscience and biobehavioral reviews·2025·
RPEP-100122025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Review of GLP-1 effects on amyloid-beta, tau, and alpha-synuclein covers how GLP-1 drugs may protect against the three major neurodegenerative protein aggregates.

Key Numbers

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Review of GLP-1 effects on amyloid-beta, tau, and alpha-synuclein covers how GLP-1 drugs may protect
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.
Published In:
Neuroscience and biobehavioral reviews, 173, 106159 (2025)
Database ID:
RPEP-10012

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Review of GLP-1 effects on amyloid-beta, tau, and alpha-synuclein covers how GLP-1 drugs may protect against the three major neurodegenerative protein aggregates.

How reliable?

Consult publication.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-10012·https://rethinkpeptides.com/research/RPEP-10012

APA

Au, Hezekiah C T; Lam, Pak Ho; Lim, Poh Khuen; McIntyre, Roger S. (2025). Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.. Neuroscience and biobehavioral reviews, 173, 106159. https://doi.org/10.1016/j.neubiorev.2025.106159

MLA

Au, Hezekiah C T, et al. "Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.." Neuroscience and biobehavioral reviews, 2025. https://doi.org/10.1016/j.neubiorev.2025.106159

RethinkPeptides

RethinkPeptides Research Database. "Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuc..." RPEP-10012. Retrieved from https://rethinkpeptides.com/research/au-2025-role-of-glucagonlike-peptide1

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.